This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

JULIUS WINSTON, M.D.

AMA Arch Otolaryngol. 1953;58(1):55-61.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE MOST important complications arising from the therapeutic use of streptomycin and dihydrostreptomycin are severe damage to the vestibular and cochlear mechanisms. Dihydrostreptomycin, which is hydrogenated streptomycin, has no therapeutic advantage over streptomycin. It was developed with the hope that it might not produce the vestibular and cochlear complications which are so frequent with the parent drug.

These antibiotics are most frequently employed by the chest physician, the general surgeon, and the urological surgeon; the otolaryngologist relatively rarely employs these agents in his practice. The otolaryngologist is, however, frequently consulted with regard to the vestibular and cochlear complications but, unfortunately, in many instances after streptomycin or dihydrostreptomycin therapy has been started or has been in progress for two or more weeks. For example, a patient who has received 1 gm. of streptomycin on one day finds that he is unable to hear his watch tick in the left ear the . . . [Full Text PDF of this Article]

Author Affiliations
PHILADELPHIA

From the Department of Otolaryngology, University of Pennsylvania School of Medicine.

Footnotes
Read before the Section on Otolaryngology of the New Jersey Chapter of the American College of Surgeons Sept. 13, 1952.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?